<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-C
REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ
INTERDEALER QUOTATION SYSTEM
FILED PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934 AND RULE 13A-17
OR 15D-17 THEREUNDER
GENZYME CORPORATION
- --------------------------------------------------------------------------------
(Exact name of issuer as specified in charter)
One Kendall Square, Cambridge, Massachusetts 02139
- --------------------------------------------------------------------------------
(Address of principal executive offices)
Issuer's telephone number, including area code: (617) 252-7500
--------------------------------
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change(increase or decrease) of five percent or more in the number
of shares outstanding:
1. Title of security: General Division Common Stock, $0.01 par value per share
---------------------------------------------------------
2. Number of shares outstanding before the change: 28,452,617 shares
----------------------------
3. Number of shares outstanding after the change: 31,327,617 shares
-----------------------------
4. Effective date of change: October 18, 1995
--------------------------------------------------
5. Method of change: Specify method (such as merger, acquisition, exchange,
distribution, stock split, reverse split, acquisition of stock for treasury,
etc): Public Offering
-------------------------------------------------------------------------
Give brief description of transaction: On October 18, 1995, Genzyme Corporation
----------------------------------------
issued 2,875,000 shares of its General Division Common Stock in a public
- -------------------------------------------------------------------------------
offering registered under the Securities Act of 1933, as amended.
- --------------------------------------------------------------------------------
II. CHANGE IN NAME OF ISSUER
1. Name prior to change:
-------------------------------------------------------
2. Name after change:
----------------------------------------------------------
3. Effective date of charter amendment changing name:
--------------------------
4. Date of shareholder approval of change, if required:
------------------------
Date: October 19, 1995 /s/ David J. McLachlan
---------------- -----------------------------------------
David J. McLachlan, Senior Vice President,
Finance and Chief Financial Officer
